
Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophy
German pharmaceutical company Boehringer Ingelheim has started the JADE Phase II clinical trial to evaluate BI 1584862 as a first-in-class oral treatment for geographic atrophy (GA). Taking place across 21 US locations, the study aims to determine the …